T A B L E O F C O N T E N T S

Background
Mortality rates among patients with sepsis, severe sepsis or septic shock are highly variable throughout different regions or services and can be upwards of 50%. Empirical broad-spectrum antimicrobial treatment is aimed at achieving adequate antimicrobial therapy, thus reducing mortality; however, there is a risk that empirical broad-spectrum antimicrobial treatment can expose patients to overuse of antimicrobials. De-escalation has been proposed as a strategy to replace empirical broad-spectrum antimicrobial treatment by using a narrower antimicrobial therapy. This is done by reviewing the patient's microbial culture results and then making changes to the pharmacological agent or discontinuing a pharmacological combination.
Objectives
To evaluate the effectiveness and safety of de-escalation antimicrobial treatment for adult patients diagnosed with sepsis, severe sepsis or septic shock caused by any micro-organism.
Search methods
In this updated version, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 10); MEDLINE via PubMed (from inception to October 2012); EMBASE (from inception to October 2012); LILACS (from inception to October 2012); Current Controlled Trials; bibliographic references of relevant studies; and specialists in the area. We applied no language restriction. We had previously searched the databases to August 2010.
Selection criteria
We planned to include randomized controlled trials (RCTs) comparing de-escalation (based on culture results) versus standard therapy for adults with sepsis, severe sepsis or septic shock. The primary outcome was mortality (at 28 days, hospital discharge or at the end of the follow-up period). Studies including patients initially treated with an empirical but not adequate antimicrobial therapy were not considered for inclusion.
Data collection and analysis
Two authors planned to independently select and extract data and to evaluate methodological quality of all studies. We planned to use relative risk (risk ratio) for dichotomous data and mean difference (MD) for continuous data, with 95% confidence intervals. We planned to use the random-effects statistical model when the estimate effects of two or more studies could be combined in a metaanalysis.
Main results
Our search strategy retrieved 493 studies. No published RCTs testing de-escalation of antimicrobial treatment for adult patients diagnosed with sepsis, severe sepsis or septic were included in this review. We found one ongoing RCT.
Authors' conclusions
There is no adequate, direct evidence as to whether de-escalation of antimicrobial agents is effective and safe for adults with sepsis, severe sepsis or septic shock. This uncertainty warrants further research via RCTs and the authors are awaiting the results of an ongoing RCT testing the de-escalation of empirical antimicrobial therapy for severe sepsis.
P L A I N L A N G U A G E S U M M A R Y
Adjustment of antimicrobial agents for adults with sepsis, severe sepsis or septic shock
Broad-spectrum antimicrobial treatment is defined as the use of an antibiotic or a combination of antibiotics which act against a wide range of disease-causing bacteria. Broad-spectrum antimicrobial treatment can reduce mortality rates in patients with sepsis, severe sepsis or septic shock. Sepsis is a serious medical condition which is characterized by an inflammatory response to an infection that can affect the whole body. The patient may develop this inflammatory response to microbes in their blood, urine, lungs, skin or other tissues. However, there is a risk that empirical broad-spectrum antimicrobial treatment can expose patients to overuse of antimicrobials and increase the resistance of micro-organisms to treatment. De-escalation has been proposed as a means of adjusting initial, adequate broadspectrum treatment by changing the antimicrobial agent or discontinuing an antimicrobial combination according to the patient's culture results (a means of identifying the microbe causing the infection). In this updated Cochrane review we searched the databases until October 2012. We found no published randomized controlled trials (RCTs). We found one ongoing RCT. There is no adequate or direct evidence on whether de-escalation of antimicrobial agents is effective and safe for adults with sepsis, severe sepsis or septic shock. Appropriate studies are needed to investigate the potential benefits proposed by de-escalation treatment.
B A C K G R O U N D Description of the condition
Sepsis is defined as a systemic inflammatory response to an infection (Bone 1992). Acute organ dysfunction caused by the infection is defined as severe sepsis, which when combined with persistent hypotension causes a condition defined as septic shock (Dellinger 2008) . There are clinical and laboratory characteristics to be considered in the diagnosis of sepsis, severe sepsis or septic shock. These include fever, hypothermia, level of consciousness and inflammatory parameters (Levy 2003) .
Irrespective of geographic and socio-economic circumstances, sepsis, severe sepsis or septic shock have been associated with mortality. In a cohort study involving 3147 patients admitted to intensive care units (ICU) in 24 European countries, the rate of sepsis was 37% (mortality rate 27%); 30% had severe sepsis (mortality rate 32%) and 15% had septic shock (mortality rate 54%) (Vincent 2006 
Description of the intervention
De-escalation has been proposed by Kollef (Kollef 2006) and consists of the following. 1. Beginning treatment with an empirical broad-spectrum antimicrobial therapy, aiming to cover the probable infectious agent(s). 2. Changing the empirical and appropriate broad-spectrum antimicrobial to a narrower-spectrum antimicrobial therapy by one of two ways:
• changing the antimicrobial agent;
• discontinuing an antimicrobial combination. 
How the intervention might work
Adequate antimicrobial therapy is associated with lower mortality rates in patients with sepsis, severe sepsis or shock septic (Harbarth 2003; McArthur 2004; Vallés 2003) . The overuse of antimicrobials, usually characterized by broad spectrum antimicrobial therapies, may be related to adverse events, extra costs (Glowacki 2003) and the emergence of bacterial resistance (Leone 2008) . Thus the use of an initial broad-spectrum antimicrobial regimen with appropriate coverage would need to be balanced against the withdrawal of unnecessary drugs. Therefore, de-escalation is essentially a proposed approach to minimize antimicrobial exposure, avoid the overuse of antibiotics, and to consequently minimize the adverse events and emergence of resistant micro-organisms (Rello 2004).
Why it is important to do this review
The main guideline on sepsis, the 'Surviving Sepsis Campaign' (Dellinger 2008), has suggested de-escalation as an option to avoid undesired manifestations associated with the overuse of antimicrobials. In view of the probable increase in de-escalation of antimicrobial therapy, the authors of this current systematic review intended to combine all existing evidence in order to improve the directions for future trials involving patients with sepsis, severe sepsis or septic shock caused by any micro-organism. The aim of this review was to assess the evidence from available randomized studies in order to improve practice in the area of sepsis.
O B J E C T I V E S
To evaluate the effectiveness and safety of antimicrobial de-escalation when compared with the maintenance of broad-spectrum therapy for adult patients diagnosed with sepsis, severe sepsis or septic shock caused by any micro-organism.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include randomized or quasi-randomized controlled trials.
Types of participants
We planned to include adult patients (aged 18 years and older) with sepsis, severe sepsis or septic shock caused by any microorganism.
Types of interventions
Our comparison groups of interest were as follows. 1. De-escalation: defined as changing an initially appropriate antimicrobial therapy from an empirical broad-spectrum characteristic to a narrower-spectrum one (by either changing the antimicrobial agent or by discontinuing an eventual antimicrobial combination, or both) according to culture results (Kollef 2001; Leone 2007; Niederman 2006) or clinical conditions.
2. Standard therapy: defined as the maintenance of an initial empirical broad-spectrum antimicrobial therapy (independent of whether the antimicrobial therapy was a combination or a single agent). We also considered de-escalation defined as the shortening of the time course of the antimicrobial therapy (for example short-course versus long-course antimicrobial therapy), trial by trial, to see whether it fulfilled the conditions for this review. We planned to consider comparison arms for analysis irrespective of the types of antimicrobial agents and possible combinations. Studies in which the patients were previously treated with an empirical but not adequate antimicrobial therapy were not considered for inclusion.
Types of outcome measures
Primary outcomes
1. Mortality at day 28 2. Mortality at hospital discharge or at the end of the followup period 
Search methods for identification of studies Electronic searches
In our original review we searched the databases to August 2010. In this updated review we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 9); MEDLINE via PubMed (from inception to October 2012); EMBASE (from inception to October 2012); and LILACS (from inception to October 2012). We used the search terms and synonyms for "sepsis", "severe sepsis", "septic shock" (clinical conditions of interest), "antimicrobial therapy" and "de-escalation" (intervention of interest) together with specialized filters for randomized controlled trials for MED-LINE and EMBASE (Appendix 1; Appendix 2; Appendix 3). We searched for ongoing trials on the Current Controlled Trials website (www.controlled-trials.com/). We did not apply any language restriction.
Searching other resources
We searched the bibliographic references of relevant studies, irrespective of study design (narrative reviews, retrospective studies, etc) with the intention of finding cited randomized studies to be included in this review; as well as conference proceedings of relevant scientific societies, published in their official journals. We contacted authors of relevant studies in the area for information on additional unpublished studies.
Data collection and analysis
Selection of studies
Two authors (BNGS and RBA) independently assessed the titles and abstracts of the identified articles to determine their potential relevance. We planned to resolve any disagreements by discussion with a third author (RS); this was not necessary for the first version of this systematic review. We planned to use the Kappa coefficient to formally test concordance between observers (Lattour 1997).
Data extraction and management
Two authors (BNGS and RBA) planned to independently extract data from each study using a data extraction form (see Appendix 4 ). We planned to resolve any disagreements by discussion with a third author (RS), but this was not necessary during preparation of the first version of this systematic review.
Assessment of risk of bias in included studies
Two authors (BNGS and RBA) planned to independently assess the methodological quality of included studies according to the study design, using the following items.
Selection bias
• Was the allocation sequence adequately generated?
• Was allocation adequately concealed?
• Were there systematic differences between the baseline characteristics of the groups that were compared?
Performance bias
• Were there systematic differences between groups in the care that was provided, or in exposure to factors other than the interventions of interest?
Detection bias
• Were there systematic differences between groups in how outcomes were determined?
Attrition bias
• Were incomplete outcome data adequately addressed?
Selective reporting bias
• Were reports of the study free of suggestion of selective outcome reporting?
Other bias
Was the study apparently free of other problems that could put it at a high risk of bias?
For each one of the above items, we planned to classify studies according to their risk of systematic error
• High risk: when the appropriate method to avoid systematic error (bias) was not met
• Moderate risk: when the appropriate method to avoid systematic error (bias) was not described or the information was not acquired by contacting the authors of the primary studies
• Low risk: when the appropriate method to avoid systematic error (bias) was met
Measures of treatment effect
For dichotomous variables, we planned to calculate the risk ratio (RR). For continuous variables, we planned to calculate the mean difference (MD) if the studies reported their results through the same variables measured with the same instruments (same units of measurement). On the other hand, when continuous data were relative to the same aspect in the patients but were measured with different instruments (and were not interchangeable units of measurement) it was intended to pool them by using standardized mean difference (SMD). The 95% confidence interval (95% CI) was to be determined for all statistical methods.
Unit of analysis issues
The unit of analysis was to be based on the individual patient. We had expected to find only parallel group study designs, not crossover studies. This is because of the natural history of sepsis, severe sepsis or septic shock. That is, the need to resolve the condition within a short time frame.
Dealing with missing data
For dichotomous data, we planned to use intention-to-treat analyses (ITT) by including all participants randomized to the intervention groups. For continuous data, we planned to try to contact the authors of the primary studies to supply missing information for participants who withdrew from the studies. We planned to analyse data based on the last individual data before the withdrawal. If we were unsuccessful in obtaining the missing data from the study authors, then we planned to perform available case analysis. If any studies did not report withdrawals, then we planned to assume that there were no withdrawals.
Assessment of heterogeneity
We planned to assess statistical heterogeneity using the I 2 statistic (Higgins 2002). We planned to assume a statistically significant heterogeneity between estimated effects of included studies when I 2 > 50%. We planned to use the random-effects model if significant heterogeneity was found.
Assessment of reporting biases
If there were a sufficient number of available studies, we had planned to assess publication bias by preparing a funnel plot. However, we were aware that asymmetry in the funnel plot can be associated with other reasons than publication bias (for example chance; real heterogeneity; clinical particularities inherent to each one of the included studies, such as patients at high risk of the outcome; etc).
Data synthesis
Qualitative data
We planned to synthesize and present qualitative information relative to methods, risk of bias, description of participants and outcomes measures and present them in the table 'Characteristics of included studies'.
Quantitative data
Irrespective of the nature of the data we planned to use the random-effects model because substantial clinical and methodological heterogeneities were expected, which by themselves could generate substantial statistical heterogeneity. When data from primary studies were not parametric (for example effects reported as medians, quartiles, etc) or are without sufficient statistical information (for example standard deviations, number of patients, etc) we planned to insert them into an 'Additional table'.
Subgroup analysis and investigation of heterogeneity
We intended to carry out subgroup analyses by type of de-escalation (guided by culture, stopping one drug of a combination, or guided by clinical signs). We planned to perform subgroup analysis according to: the type of infectious agent, fungi or bacteria; and site of infection (for example gastrointestinal, urinary, respiratory, abdominal, and surgical focus). We planned that heterogeneity in both the direction and length of estimate effect between subgroups would be assumed as a suspected causal relationship between them (the subgroup characteristic and the estimate effect).
Sensitivity analysis
We planned to use sensitivity analyses to examine the effects of study quality and any trials that were only reported as abstracts.
This will be performed in updated versions of this systematic review.
R E S U L T S Description of studies
See: Characteristics of excluded studies; Characteristics of ongoing studies.
Results of the search
Our sensitive search strategy yielded 158 references in MEDLINE (PubMed), 52 in EMBASE, 302 in The Cochrane Library, 12 studies in Current Controlled Trials, and two in LILACS; and one ongoing trial by contacting the specialists in the area. We did not retrieve any studies in the reference lists of the main articles. After discarding duplicates we identified 493 publications. Because of the lack of suitable studies in this area the two authors (BNGS and RBA), after screening the references by title and abstract, initially selected 71 studies. Although most were not RCTs they expressed the idea of a 'more restrictive' or 'rational' use of antimicrobial regimens or made suggestions about adjustment of an initial and empirical broad-spectrum antimicrobial therapy to a narrowed-spectrum antimicrobial therapy, irrespective of their inclusion criteria (participants) and study design. Of these 71 studies, 59 were not considered suitable because of their study design (Appendix 5). The 59 studies were comprised of 22 observational studies (cohort, case-control, or prevalence studies), one an in vitro study, one a guideline, and 34 narrative or systematic reviews (including the previous version of this own systematic review). We did not calculate the Kappa coefficient because none of these studies met our inclusion criteria. For more details, see Figure 1 .
Included studies
We did not include any studies in this updated review.
Excluded studies
We excluded the remaining 12 references either because their interventions were not of interest (Bailey 1996 1. monitoring by procalcitonin (inflammatory marker) levels, or 2. a control group. The patients' antibiotics were commenced or ceased based on procalcitonin concentrations. The patients were not randomized to have an initial empirical, broad-spectrum antimicrobial therapy which was adjusted according to their culture results or clinical condition. Therefore, these four studies were not considered suitable for inclusion in this review.
Risk of bias in included studies
There was no eligible study.
Allocation
This category was not evaluated since no eligible study was found.
Blinding
Incomplete outcome data
Selective reporting
Other potential sources of bias
Effects of interventions
D I S C U S S I O N Summary of main results
We found no adequate, direct evidence as to whether de-escalation of antimicrobial agents is effective and safe for adults with sepsis, severe sepsis or septic shock.
Overall completeness and applicability of evidence
We hope the information available in this systematic review will encourage researchers and specialists to test the de-escalation of antimicrobial agents with the methodological rigour inherent in randomized controlled trials. Currently, there is no available evidence to recommend or not the de-escalation of antimicrobial agents in clinical practice for septic patients. This lack of evidence justifies future randomized controlled trials or cohort studies. However, some clinical and methodological particularities should be considered (for example new infectious focus, recurrence, any intercurrent event needing changes in the antimicrobial therapy, or unavailability of microbiological culture) to avoid additional risks of harms (for example worsening of clinical condition, mortality). We offer a simplified model of patient flow for future randomized trials in this area, see Figure 2 .
Figure 2. A simplified patients' flow for future randomized controlled trials testing the de-escalation of
We suggest sample sizes for two hypothesis.
Absence of difference in mortality between comparison groups (de-escalation versus control)
• Baseline risk of 27% for mortality among septic patients (Vincent 2006) • Assumed relative risk reduction of 10% for mortality in the de-escalation group, corresponding to 24% of mortality (risk difference between comparison groups 3%) 4599 patients would be needed for each one of the comparison groups, according to the formula n = [2P C ·(1-P C )·(Zα+Zβ) 2 ]·(P E -P C ) −2 (Pocock 1983), where P C = 27%; P E = 24%; Zα = 1.96; Zβ = 1.28.
Reduction of mortality in the de-escalation group (indirect evidence obtained from observational study in ventilatorassociated pneumonia)
• Baseline risk of 27% for mortality among septic patients (Vincent 2006) • Indirect evidence of relative risk reduction of 28% for mortality in the de-escalation group in patients with ventilatorassociated pneumonia, corresponding to a mortality rate of 19% in the de-escalation group (risk difference between comparison groups of 8%) (Kollef 2006) 323 patients would be needed for each one of the comparison groups, according to the formula n = [P E ·(1-P E )·(Zα+Zβ) 2 ]·(P E -P C ) −2 (Pocock 1983), where P C = 27%; P E = 19%; Zα = 1.96; Zβ = 1.28.
Quality of the evidence
We found a complete absence of direct evidence regarding the de-escalation of antimicrobial agents for adults with sepsis, severe sepsis or septic shock.
Potential biases in the review process
The high sensitivity of the search strategy we used in this systematic review should guarantee a low probability that we have missed any randomized controlled trials which would fulfil our inclusion criteria. Language bias was prevented by not imposing any language restriction. Other methodological issues of this review, such as data collection and analysis, cannot be judged since no adequate study could be found.
Agreements and disagreements with other studies or reviews
The World Health Organization and other health organizations have been encouraging the selection of interventions to minimize microorganisms that are resistant to antimicrobial agents, with important implications for world health and the economy (IDSA 2006; WHO 2002) . Thus, several authors support the deescalation of antibiotics as a reasonable strategy to achieve this aim besides the minor adverse events and costs (Heenen 2012; Masterton 2011; Morel 2010; Shime 2011) . In a narrative review, Deresinski 2007 suggests the de-escalation of antimicrobial antibiotics in ICUs according to patients' culture results and their clinical evolution. Available guidelines, specifically the 'Surviving Sepsis Campaign', have also suggested de-escalation of antimicrobial agents for adults with sepsis, severe sepsis or septic shock based on specialists' opinions or indirect evidence (Dellinger 2008).
A U T H O R S ' C O N C L U S I O N S Implications for practice
There is no adequate evidence as to whether de-escalation of antimicrobial agents is, or is not, effective and safe for adults with sepsis, severe sepsis or septic shock.
Implications for research
The information available in this systematic review should encourage researchers and specialists to test the de-escalation of antimicrobial agents with the methodological rigour inherent in randomized controlled trials. This lack of information justifies future randomized controlled trials or cohort studies considering ethical, epidemiological and economical points of views. However, several clinical particularities as well as operational or methodological circumstances have to be better understood. Specific inclusion criteria and reasons for protocol deviations may be adopted to avoid additional risks of harms. Future trials can test for two hypothesis:
1. absence of difference in mortality between the de-escalation and the control groups (maintained empirical broad-spectrum antimicrobial therapy) (n ≃ 4600 patients for each of the comparison groups); 2. relative risk reduction of 28% for mortality in the deescalation group, considering the mortality baseline risk of 27% (n ≃ 323 for each of the comparison groups).
The authors of this review are awaiting the results of an ongoing randomized controlled trial by Leone 2012.
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R E F E R E N C E S
References to studies excluded from this review • Subject having a sepsis engraves (burns) defined according to the following criteria during the initiation of the probability antibiotic treatment:
• criteria of SIRS [14 ] , and • a suspected infection, and • a failure of organ: low blood pressure, respiratory failure, coma, hepatic insufficiency, renal insufficiency, thrombopenia, spontaneous extension of the TCA.
• Subject for which an antibiotic treatment was begun within 6 hours following the diagnosis of sepsis engraves (burns).
• Subject for which taking the microbiological aim was made within 48 hours following the diagnosis of sepsis. 
D A T A A N D A N A L Y S E S
This review has no analyses. 
A P P E N D I C E
W H A T ' S N E W
Last assessed as up-to-date: 31 October 2012.
Date Event Description
February 2013 New citation required but conclusions have not changed
We found no published randomized controlled trials (RCTs). We found one ongoing RCT (Leone 2012).
18 February 2013 New search has been performed In the previous version (Silva 2010) we searched the databases until August 2010.
In this updated version, we reran the searches until October 2012 
C O N T R I B U T I O N S O F A U T H O R S
